$XBIO Cashflow Statement | Understand Stock

$XBIO

$1.85 +$0.13 (7.56%) Close

$XBIO Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss)
Adjustments to reconcile net loss to net cash used in operating activities:
Asset impairment charges
Deferred income taxes
Depreciation
Acquired in-process research and development
Amortization of right of use asset
Gain on settlement with vendor
Share-based expense
Changes in operating assets and liabilities:
Prepaid expenses and other
Other long-term assets
Accounts payable, accrued expenses and other current liabilities
Net cash used in operating activities
Net cash paid to acquire in-process research and development
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from issuance of common stock and warrants
Net proceeds from issuance of common stock
Net proceeds from issuance of common stock in October 2025 underwritten public offering
Proceeds from exercise of warrants
Net cash provided by financing activities
Net change in cash
Cash at beginning of period
Cash at end of period
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for interest
SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Right of use asset obtained in exchange for lease liability
Issuance of common stock to acquire in-process research and development
Issuance of common stock to vendor
Issuance of common stock in connection with warrant buyout
Issuance of common stock from cashless exercise of purchase warrants
Issuance of common stock to adjust for Reverse Stock Split
Conversion of Series A preferred stock to common stock
Conversion of Series B preferred stock to common stock

Comments